Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.68 |
| ▸ | TLK2 | Q86UE8 | 2/20 | 0.68 |
| ▸ | FLT3 | P36888 | 2/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.65 |
| ▸ | MET | P08581 | 1/20 | 0.65 |
| ▸ | PRKAA1 | Q13131 | 11/20 | 0.64 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 10/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114656 | 1.00 | KDR (0.68) | KDRPDGFRBFGFR1TLK2FLT3 | |
| SCHEMBL31672525 | 0.92 | KDR (0.65) | KDRPDGFRBFGFR1TLK2FLT3 | |
| SCHEMBL4559099 | 0.92 | KDR (0.65) | KDRPDGFRBFGFR1TLK2FLT3 | |
| SCHEMBL2114007 | 0.92 | KDR (0.65) | KDRPDGFRBFGFR1TLK2FLT3 | |
| SCHEMBL31672506 | 0.92 | KDR (0.70) | KDRPDGFRBFGFR1TLK2FLT3 | |
| SCHEMBL2114207 | 0.92 | KDR (0.70) | KDRPDGFRBFGFR1TLK2FLT3 | |
| SCHEMBL13755214 | 0.92 | KDR (0.70) | KDRPDGFRBFGFR1TLK2FLT3 | |
| SCHEMBL13755226 | 0.86 | KDR (0.65) | KDRPDGFRBFGFR1TLK2FLT3 | |
| SCHEMBL2114979 | 0.86 | KDR (0.65) | KDRPDGFRBFGFR1TLK2FLT3 | |
| SCHEMBL13755236 | 0.86 | KDR (0.65) | KDRPDGFRBFGFR1TLK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1255752-B1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | KDR 648/4885PDGFRB 40/4885FGFR1 48/4885 |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | KDR 1387/4885PDGFRB 1034/4885FGFR1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.